Rabeprazole
- Generic Name
- Rabeprazole
- Brand Names
- Aciphex, Pariet
- Drug Type
- Small Molecule
- Chemical Formula
- C18H21N3O3S
- CAS Number
- 117976-89-3
- Unique Ingredient Identifier
- 32828355LL
- Background
Rabeprazole is an antiulcer drug in the class of proton pump inhibitors. It is a prodrug - in the acid environment of the parietal cells it turns into active sulphenamide form. Rabeprazole inhibits the H+, K+ATPase of the coating gastric cells and dose-dependent oppresses basal and stimulated gastric acid secretion.
- Indication
For the treatment of acid-reflux disorders (GERD), peptic ulcer disease, H. pylori eradication, and prevention of gastroinetestinal bleeds with NSAID use.
- Associated Conditions
- Duodenal Ulcer, Gastric Ulcer, Gastro-esophageal Reflux Disease (GERD), Heartburn, Helicobacter Pylori Infection, Non-erosive Reflux Esophagitis Disease (NERD), Vomiting, Zollinger-Ellison Syndrome, Develop NSAID-induced gastric ulcers, Erosive reflux esophagitis
A Study of the Safety and Effectiveness of Rabeprazole for the Treatment of Gastroesophageal Reflux Disease (GERD) in Pediatric Patients
- First Posted Date
- 2008-11-10
- Last Posted Date
- 2013-01-24
- Target Recruit Count
- 127
- Registration Number
- NCT00787891
Double-blind Comparative Study of E3810 Tablets (10 or 20 mg b.i.d.) to Evaluate Efficacy and Safety in Patients With Refractory Reflux Esophagitis
- First Posted Date
- 2008-10-10
- Last Posted Date
- 2012-04-18
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 337
- Registration Number
- NCT00770913
A Pharmacokinetic and Safety Study of Single and Multiple Doses of Rabreprazole in Pediatric Patients With Gastroesophageal Reflux Disease (GERD) 1 to 11 Years Old, Inclusive
Phase 1
Completed
- Conditions
- GERD
- First Posted Date
- 2008-09-05
- Last Posted Date
- 2011-01-10
- Target Recruit Count
- 31
- Registration Number
- NCT00747695
A Study of Single and Multiple Doses of Rabeprazole in Pediatric Patients With Gastroesophageal Reflux Disease (GERD) 1 to 11 Months Old, Inclusive
Phase 1
Completed
- Conditions
- Gastroesophageal Reflux Disease (GERD)
- Interventions
- First Posted Date
- 2008-09-05
- Last Posted Date
- 2013-07-08
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 51
- Registration Number
- NCT00747526
A Comparative Study of Proton-pump Inhibitor Tests for Chinese Reflux Patients in Relation to the CYP2C19 Genotypes
- First Posted Date
- 2008-05-20
- Last Posted Date
- 2013-12-11
- Lead Sponsor
- National Taiwan University Hospital
- Target Recruit Count
- 178
- Registration Number
- NCT00681005
Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)
Phase 3
Completed
- Conditions
- Gastroesophageal Reflux Disease (GERD)
- Interventions
- First Posted Date
- 2008-04-15
- Last Posted Date
- 2015-12-21
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 1061
- Registration Number
- NCT00658528
Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD)
Phase 3
Completed
- Conditions
- Gastroesophageal Reflux Disease (GERD)
- Interventions
- First Posted Date
- 2008-04-15
- Last Posted Date
- 2016-05-04
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 1397
- Registration Number
- NCT00658632
Rabeprazole Extended-Release, 50 mg, Versus Esomeprazole, 40 mg, for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)
Phase 3
Completed
- Conditions
- Gastroesophageal Reflux Disease (GERD)
- Interventions
- First Posted Date
- 2008-04-15
- Last Posted Date
- 2015-12-21
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 1069
- Registration Number
- NCT00658775
Fasting Study of Rabeprazole Sodium Delayed-Release Tablets 20 mg to Aciphex® Delayed-Release Tablets 20 mg
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2008-04-01
- Last Posted Date
- 2024-04-24
- Lead Sponsor
- Mylan Pharmaceuticals Inc
- Target Recruit Count
- 72
- Registration Number
- NCT00648349
- Locations
- 🇺🇸
PRACS Institute, Ltd., Fargo, North Dakota, United States
Fed Study of Rabeprazole Sodium Tablets 20 mg and Aciphex® Tablets 20 mg
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2008-04-01
- Last Posted Date
- 2024-04-23
- Lead Sponsor
- Mylan Pharmaceuticals Inc
- Target Recruit Count
- 72
- Registration Number
- NCT00649493
- Locations
- 🇺🇸
PRACS Institute, Ltd., Fargo, North Dakota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath